Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Aug;154(2 Pt 1):379-83; discussion 383-4.
doi: 10.1097/00005392-199508000-00013.

Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer

M F Sarosdy  1 , R W deVere White, M S Soloway, J Sheinfeld, M A Hudson, P F Schellhammer, M V Jarowenko, G Adams, B A Blumenstein
Affiliations
Free article
Clinical Trial

Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer

M F Sarosdy et al. J Urol. 1995 Aug.
Free article

Abstract

Objectives: We compare the Bard BTA (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer.

Materials and methods: A prospective, blinded, multicenter trial was performed.

Results: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was more sensitive than cytology studies in detecting recurrent cancer (p < 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9%.

Conclusions: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

PubMed Disclaimer

Comment in

Substances